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Abstract
In the mid-1990's, researchers hypothesized, based on new viral load data, that HIV-1 causes CD4+
T-cell depletion by direct cytopathic effect. New data from non-human primate studies has raised
doubts about this model of HIV-1 pathogenesis. Despite having high levels of viremia, most SIV
infections are well tolerated by their natural hosts. Two recent studies of these models provide
information, which may be useful in determining how HIV-1 causes CD4+ T-cell loss. A full
understanding of pathogenesis may lead to novel therapies, which preserve the immune system
without blocking virus replication.
Discussion
HIV-1 infection is characterized by an insidious deteriora-
tion of the cellular immune system[1]. Both the quantity
and proportion of plasma CD4+ T-cells decrease steadily
over a period of years to decades, and this progressive loss
of CD4+ T-cells is associated with the development of
acquired immunodeficiency syndrome (AIDS) in infected
individuals. The degree of immunodeficiency associated
with HIV-1 infection, as defined by the onset of opportun-
istic diseases, correlates closely with plasma CD4+ T-cell
counts. Moreover, the rate at which immunosuppression
develops also closely reflects the levels of HIV-1 RNA in
plasma, such that the higher the HIV-1 viral load, the
greater the loss of circulating CD4+ T-cells per year. A dec-
ade ago, researchers believed that the CD4+ T-cell deple-
tion seen in the plasma compartment was reflective of the
total CD4+ T-cell pool and that virus replication was driv-
ing the slow loss of cells[2]. The seemingly direct relation-
ship of HIV-1 replication with systemic CD4+ T cell loss
and immunosuppression was made famous by the quote
"It's the virus, stupid[3]", a humorous but pointed refer-
ence to the apparent "cause-and-effect" nature of this con-
nection. Over the past few years, in light of new data,
experts are now questioning this hypothesis.
It is now widely appreciated that both HIV-1 infection in
humans, and simian immunodeficiency virus (SIV) infec-
tion in rhesus macaques (Macaca mulatta), are associated
with destruction of the vast majority of memory CD4+ T-
cells in the gastrointestinal tract in the first few weeks after
infection [4-13]. Although mucosal tissues harbor a large
percentage of the total CD4+ T-cell population, this pro-
found destruction is not reflected in the plasma cell pool.
The depleted, mucosal CD4+ T-cells are not completely
replaced and the host remains deficient in memory CD4+
T-cells. Some speculate that the GI tract is not unique and
that a widespread mucosal immunodeficiency occurs very
early after infection. In this altered state, the mucosal lym-
phocytes do not appropriately or adequately control
invading organisms. This lack of control then contributes
to a more generalized activation of the immune system,
which is seen during the chronic phase of HIV-1 infection
[14]. The level of immune system activation correlates
with viral load and independently with the rate of CD4+
T-cell depletion. Of the many activation markers, the pres-
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ence of increased CD38 on CD8+ T-cells correlates best
with the rate of disease progression[15,16]. Many now
believe chronic immune activation, not simply HIV-1 rep-
lication, leads to progressive depletion of the remaining
CD4+ T-cells.
Much of the new data in support of this concept comes
from non-human primate models of HIV infection. More
than 30 monkeys and apes are naturally infected with dis-
tinct strains of SIV [17], and most of these viruses are well
tolerated by their natural hosts. As a case in point, both
sooty mangabeys (Cercocebus torquatus atys) and African
green monkeys (Chlorocebus spp.) are the natural hosts for
SIVsmm and SIVagm, respectively. In each case, SIV repli-
cates to high levels, but the virus does not cause circulat-
ing CD4+  T-cell lymphopenia or immunodeficiency.
However, experimental infection of rhesus macaques with
SIVsmm, or other closely related strains of SIV, does cause
a disease very similar to AIDS. Investigators have been try-
ing to understand why SIV infection causes disease in
some monkeys, but not others, as a means of unraveling
the basis for immunodeficiency in humans infected with
HIV-1. Reports from two recent studies now shed light on
this paradox.
In the June issue of Cell, Schindler et al. report that nef,
which is present in all primate lentiviruses, may protect
the natural host by modulating expression of the T-cell
receptor-CD3 complex (TCR-CD3)[18]. Nef is a small len-
tiviral protein with many attributed functions, including
down regulation of CD4, CD28, and MHC-I. The authors
analyzed 30 nef alleles from 30 different primate lentivi-
ruses. All of the nef alleles down regulated CD4 and MHC-
I molecules from the cell surface. Most also down regu-
lated TCR-CD3 efficiently. However some, including
those of HIV-1 and SIVcpz (a close relative of HIV-1), had
no effect on TCR-CD3 cell surface expression [see Figure
1]. T-cells expressing nef alleles that were able to down
modulate TCR-CD3 had decreased levels of activation
after PHA stimulation. Further, expression of these nef
alleles in peripheral blood mononuclear cells (PBMC)
protected the cells against PHA-induced apoptosis. In
contrast, those nef alleles that did not reduce cell surface
expression of TCR-CD3 were found to increase T-cell acti-
vation and apoptosis.
The authors noted that the TCR-CD3-downmodulating
nefs belong to viruses such as SIVsmm that do not cause
disease in their natural hosts. This newly described activity
of nef may be linked with the maintenance of an intact
immune system in SIVsmm-infected sooty mangabeys.
SIV plasma levels in sooty mangabeys typically exceed
those of HIV-1 in humans [19-21]. Yet, sooty mangabeys
do not develop immunodeficiency. By comparison, HIV-
1 nef does not affect the TCR-CD3 complex and this may,
in turn, contribute to aberrant activation of the immune
system and the gradual erosion of immune function asso-
ciated with AIDS.
Many questions remain regarding this hypothesis. In the
chronic phase of infection, HIV-1 infects only a small
minority (<1.0%) of CD4+ T-cells [22], yet a much higher
percentage of many different cell types possess the acti-
vated phenotype [23]. How does increased activation or
apoptosis of a small percentage of CD4+ T-cells (those
infected with HIV-1) lead to activation of large popula-
tions of uninfected cells? Like HIV-1 nef, the nef gene of
SIVcpz also does not down regulate the TCR-CD3 com-
plex, and yet most chimpanzees infected with SIVcpz do
not develop immune system activation or CD4+ T-cell
lymphopenia [24][25][26][27]. As discussed in the Cell
article, SIVmac nef has TCR-CD3 down-regulating activity.
If so, why do SIVmac-infected rhesus macaques have
highly activated immune systems? Finally, what is the
evolutionary advantage of HIV-1 without this activity? If
the virus, which decreases TCR-CD3 expression, can repli-
cate to high levels, how does the loss of this function of nef
make HIV-1 more fit? Future studies are clearly needed to
address these questions.
Another study of relevance to this topic was recently pub-
lished in Retrovirology[28]. Ploquin et al. compared the
non-pathogenic SIVagm infection of African green mon-
keys with the virulent infection of rhesus macaques with
SIVmac. The authors measured both pro-(TNF-α and IFN-
γ) and anti-(IL-10) inflammatory cytokines after in vivo
infection. The levels of TNF-α and IFN-γ transcripts in
PBMC increased significantly in rhesus macaques in the
first two weeks of infection with SIVmac. In contrast, TNF-
α and IFN-γ expression did not change during this time in
African green monkeys infected with SIVagm. Differences
were also noted in expression of IL-10, a negative regula-
tor of inflammation, which increased in the African green
monkeys at days 10–16 post-infection, but was not up-
regulated in SIVmac-infected macaques. The authors
found that smad4, a key intracellular, downstream signal
of TGFβ-1 binding, was also up-regulated in infected Afri-
can green monkeys. TGFβ-1 is an important, anti-inflam-
matory cytokine and these data support the hypothesis
that a pro-inflammatory state is associated with patho-
genic SIV infection.
Each of these new articles strongly supports the concept
that immune activation, at least in part, drives CD4+ T-cell
depletion, whereas viremia alone is not sufficient to cause
clinically significant immunodeficiency. When general-
ized immune system activation and viremia appear
together, as in the case of HIV-infected humans and SIV-
infected macaques, disease occurs. Modulation of TCR-
CD3 may help prevent activation of the immune systemRetrovirology 2006, 3:60 http://www.retrovirology.com/content/3/1/60
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SIV (left panel) and HIV (right panel) infected CD4+ T-lymphocytes Figure 1
SIV (left panel) and HIV (right panel) infected CD4+ T-lymphocytes. Following infection, each produces Nef, which associates 
with the cell membrane. However, only SIV Nef downregulates the T-cell receptor complex (TCR). HIV infected cells still 
express the TCR and are more prone to activation and apoptosis.Retrovirology 2006, 3:60 http://www.retrovirology.com/content/3/1/60
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in non-pathogenic infections, while localized CD4+ T-cell
depletion at the mucosal surfaces may allow antigenic
stimulation and activation of the remaining cells. Pro-
inflammatory cytokines are also likely to play a role: CD8+
T-cells are activated and not infected with HIV/SIV, B-cells
and NK cells are also activated. The level of immune acti-
vation drastically decreases with effective HIV therapy
[29][30][31][32][33][34]. However, cellular activation
markers do not return to normal levels even when viremia
is undetectable. In most HIV-positive patients, viral sup-
pression leads to large increases in their plasma CD4+ T-
cell counts. Those with little or no change in their CD4+ T-
cell counts generally have persistent immune system acti-
vation [35].
Using non-human primate models, researchers hope to
delineate the HIV-induced immune activation pathways.
Such a discovery could lead to innovative new therapies
that specifically block activation of the immune system.
While inhibiting HIV-1 replication during chronic infec-
tion makes sense, it is not the true goal of HIV treatment.
We treat HIV to prevent or slow the development of
immunodeficiency. A therapy that preserves the immune
system without inhibiting virus replication would cer-
tainly be a welcome addition to currently available
antiretroviral drugs that target HIV but do not adequately
restore immune function.
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